Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Takeda Makes $1 Billion Move For Amgen Development Rights

This article was originally published in PharmAsia News

Executive Summary

Eyeing the looming 2011 patent expiration of its top-seller Actos (pioglitazone), Takeda has acquired exclusive Japanese development and commercialization rights, and in one case global rights, to 13 of Amgen's clinical candidates, at a potential cost of up to $1.2 billion

You may also be interested in...



Deals Of The Week Watches Crowdfunders Multiply Like Rabbits

VentureHealth combines the best in venture and crowdfunding, and has two exits to show for it. Plus Valeant buys Bausch & Lomb, GSK buys Okairos, AZ buys Omthera, while ThromboGenics/Array, Pfizer/UCSF, and Amgen/Astellas do deals.

“Now Is The Time” For Japan, Amgen Says; Inks Strategic Alliance With Astellas

After selling off its Japanese subsidiary in 2008, Amgen returns via an alliance and joint venture with Astellas, with the goal of establishing a wholly owned affiliate by 2020. But challenges remain in a country known for long memories.

“Now Is The Time” For Japan, Amgen Says; Inks Strategic Alliance With Astellas

After selling off its Japanese subsidiary in 2008, Amgen returns via an alliance and joint venture with Astellas, with the goal of establishing a wholly owned affiliate by 2020. But challenges remain in a country known for long memories.

Related Content

Latest News
See All
UsernamePublicRestriction

Register

SC067824

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel